CLVS2

Across TCGA pan-cancer cohorts, CLVS2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CLVS2 data layer compared with 28 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher CLVS2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLVS2 expression acts as an unfavorable survival marker.

MESO, COAD, and LUAD are the cancer types where CLVS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.130	0.557	.019	18	view →
COAD	OS	Median	III,IV	0.157	0.791	.001	12	view →
LUAD	OS	Median	III,IV	0.083	0.680	<.001	12	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CLVS2–MESO (OS)

Open the MESO breakdown →